论文部分内容阅读
对35例胰腺癌、12例正常胰腺组织、26例胰腺良性疾病、8例壶腹癌及7例胆管癌行FNAB,并对FNAB残余物行PCR-SSP检测K-ras基因有无突变。结果:FNAB对胰腺癌的确诊率为57.1％(20/35),对壶腹癌及胆管癌的确诊率分别为50％(4/8)、57.1％(4/7),PCR-SSP对胰腺癌的确诊率为91.4％(32/35),对壶腹癌及胆管癌确诊率皆为0。研究表明:FNAB与PCR-SSP检测K-ras基因有无突变相结合,可以协同诊断胰腺癌;PCR-SSP对壶腹癌及胆管癌诊断价值不大。
FNAB was performed in 35 cases of pancreatic cancer, 12 cases of normal pancreatic tissue, 26 cases of benign pancreatic disease, 8 cases of ampullary carcinoma, and 7 cases of cholangiocarcinoma. PCR-SSP was used to detect K-ras gene mutation in FNAB residue. Results: The diagnosis rate of FNAB in pancreatic cancer was 57.1% (20/35). The confirmed diagnosis rate of ampullary carcinoma and cholangiocarcinoma were 50% (4/8) and 57.1% (4/7) respectively. PCR-SSP The diagnosis rate of pancreatic cancer was 91.4% (32/35). The diagnosis rate of ampullary carcinoma and cholangiocarcinoma was 0. Studies have shown that: FNAB and PCR-SSP detection of K-ras gene mutations combined, can be used to diagnose pancreatic cancer; PCR-SSP diagnosis of ampullary carcinoma and cholangiocarcinoma have little value.